Biogen cuts price of controversial Aduhelm in half
Dec 21, 2021
The drug shows promise in clearing the brain plaques believed to play a role in Alzheimer’s disease.
Biden pledges to lower prescription drug prices for Americans
Dec 07, 2021
But the biggest policy change — letting Medicare negotiate prices for prescription drugs — will not start to lower costs until 2025.
Pricey Alzheimer drug drives spike in Medicare B premium: Officials
Nov 15, 2021
New premium will be $170.10 a month, and the $21.60 boost is the biggest increase ever in dollar amount, but not in percentage terms
States overlooking untapped potential of dual-eligible special needs plans: report
By
Kimberly Bonvissuto
Oct 28, 2021
The American Rescue Plan Act is expected to infuse $11 billion in federal dollars to states to bolster home- and community-based services in Medicaid. But few states are connecting the dots on how integrated...
Medicare claims data can aid development decisions: NIC MAP Vision
By
Kathleen Steele Gaivin
Oct 05, 2021
Operators trying to determine which markets are under- or over-served can use Medicare data to make better development decisions, according to Arick Morton, CEO of NIC MAP Vision.
MA plans ‘designed for senior living residents by senior living communities’ roll out in California
By
Kimberly Bonvissuto
Sep 10, 2021
LeadingAge California and Richmond, VA-based care management company AllyAlign Health are partnering to offer Medicare Advantage special needs plans to cover long-term care residents across the continuum...
More news for Wednesday, July 14
By
Alicia Lasek
Jul 14, 2021
Medicare to weigh national coverage for Aduhelm, other Alzheimer’s treatments … Neurologists issue ethical guidance for dementia diagnosis and care … Helping seniors hear better may slow decline...
Medicare mulls coverage for controversial drug for Alzheimer’s disease
Jul 13, 2021
CMS says a final decision on coverage is not likely until next spring.
New Rx instructions tighten use of controversial Alzheimer’s disease drug
Jul 08, 2021
Major changes to prescribing instructions are rare, especially so soon after approval; it change could curb the drug’s use.
A very troubling $56 billion question
By
John O'Connor
Jul 08, 2021
Considering some of the alternatives, I’m far from convinced that bankrupting Medicare for the sake of Aduhelm would be money well spent.